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 Cecilia Lo, PhD 
 
                                                      ABSTRACT 
 
Hypoplastic left heart syndrome (HLHS) is a complex congenital heart defect characterized by 
severe hypoplasia of the left ventricle (LV) along with stenosis/atresia of the aortic and mitral 
valves.  HLHS patients show an incidence of 4-9 in 100,000 live births.  Clinical studies have 
indicated that HLHS is a complex disease that is heritable, but no specific gene(s) have been 
identified.  Despite the recent surgical advancements in the treatment of HLHS, understanding 
the developmental and genetic mechanisms associated with HLHS have proved to be a challenge 
due to the lack of an animal model.  
In our study, we recovered 7 mutant mouse lines with HLHS from a large-scale recessive 
genetic screen with ENU mutagenesis. Further analysis of one HLHS mutant line, Ohia, showed 
that the HLHS phenotype is indeed heritable. Whole exome sequencing of two Ohia HLHS 
mutants revealed both were homozygous for mutations in five genes: Prolidase, NAD synthetase, 
Protocadherin a9, Sin3A-associated polypeptide 130 and N-acetyltransferase-ESCO1.  GO term 
and KEGG ontology analysis of RNAseq data from heart tissue of E13.5,E14.5 and E18.5 Ohia 
mutants and littermate controls showed down-regulation of many genes involved in 
mitochondrial dynsfunction, such as oxidative phosphorylation,  Parkinson’s, and Alzheimer’s 
disease .  Genes involved in pathways of cancer, extracellular matrix-receptor interaction, focal 
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adhesion, TGF-beta signaling, and Wnt signaling showed up regulation. These pathway 
enrichments are similar to results previously shown with microarray transcript profiling of 
human HLHS heart tissue.   
In conclusion, we have generated the first mouse model for HLHS and showed it closely 
mirror not only the structural heart defect but also the metabolic changes seen in human HLHS 
patients.  Using this mouse HLHS model, we will be able to interrogate the developmental 
pathways and molecular etiology underlying HLHS. Dissecting these elements would prove to 
be of immense public health significance, as despite the medical advances, every year 4-9 
children in 100,000 live births are born with HLHS, and very few make it to adulthood.  HLHS 
is universally fatal with 90% of deaths occurring in the first month of life in the absence of 
surigical treatment.  
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1.0 INTRODUCTION 
1.1 CONGENITAL HEART DEFECTS 
Congenital heart defects (CHD) are the most common type of birth defect. They affect 8 out of 
every 1,000 newborns. Each year, more than 35,000 babies in the United States are born with 
congenital heart defects [NIH, 2011]. CHD are an important cause of childhood morbidity and 
mortality worldwide [Bruneau BG, 2008]. Despite recent advances in medical and surgical care, 
the etiology of CHD is yet to be elucidated. Studies such as the Baltimore-Washington Infant 
Study have found that CHD is multifactorial, with both genetic and environmental contributing 
factors. [Ferencz C. et al 1993].  Gene targeting has aided in the generation of a several mouse 
models with cardiac developmental defects. Studies like these have led to the identification of 
multiple transcriptional regulators, structural genes and signaling molecules that are critical for 
normal cardiac development [Ashleigh A Richards et al, 2010]. 
CHD are often associated with a wide variation of phenotypes, making them a complex 
disorder with complex underlying mechanisms. The genetic etiology has thus been difficult to 
determine. CHD have a limited correlation between the genetic mutation and the specific 
phenotype. Some reasons underlying the complexity of CHD include:  genetic heterogeneity in 
which similar cardiac defects are caused by more than one genetic mutation [Benson 2000]; 
variable expressivity in which one gene may cause multiple phenotypes [Benson 2000]; reduced 
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penetrance where a person may be a carrier for the disease-causing mutation but not express the 
CHD phenotype [Benson 1998]; one or more causative genes for CHD associated with 
chromosomal alterations [Momma 1995]; single gene defects with or without the expression of 
the CHD phenotype [McElhinney 2002] . 
Congenital heart diseases affect most parts of the heart (Fig. 1).  CHD can be classified 
into three broad categories; cyanotic heart disease, left-sided obstruction defects and septation 
defects.  Left-sided obstructive lesions, the second main type of congenital heart disease, include 
hypoplastic left heart syndrome (HLHS), mitral stenosis, aortic stenosis, aortic coarctation and 
interrupted aortic arch (IAA) [Bruneau BG, 2008]. 
 
 
Figure 1. Adult Health and the Structures that are affected by CHD. 
AC, aortic coarctation; AS, aortic stenosis; ASD, atrial septal defect; AVSD, atrioventricular septal defect; BAV, 
bicuspid aortic valve; DORV, double outlet right ventricle; Ebstein’s, Ebstein’s anomaly of the tricuspid valve; 
HLHS, hypoplastic left heart syndrome; HRHS, hypoplastic right heart; IAA, interrupted aortic arch; MA, mitral 
atresia; MS, mitral stenosis; PDA, patent ductus arteriosus; PS, pulmonary artery stenosis; PTA, persistent truncus 
arteriosus; TA, tricuspid atresia; TAPVR, total anomalous pulmonary venous return; TGA, transposition of the great 
arteries; TOF, tetralogy of Fallot; VSD, ventricular septal defect. [Bruneau BG, 2008] 
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1.2 HYPOPLASTIC LEFT HEART SYNDROME 
Hypoplastic left heart syndrome (HLHS, OMIM: #241550) (Fig. 2) is characterized by 
abnormally developed atrial septum and a severe underdevelopment of the left side of the heart, 
including hypoplasia of the left ventricle, aortic atresia/ stenosis and mitral valve atresia/ 
stenosis. [Madhu Gupta et. al 2008] 
Figure 2. Hypoplastic Left Heart Syndrome Heart Structure. 
The four main defects are shown; patent ductus arteriosus, hypoplastic left ventricle, atrial septal 
defect and hypoplastic aorta. Blood flow indicated by direction of arrows. 
http://www.childrenshospital.org/az/Site502/mainpageS502P0.html)  
This rare disorder occurs in about 0.16-0.36 of every 1,000 live births (www.orpha.net) 
and has a higher prevalence in males than females. HLHS comprises 1.2 -1.5% of all congenital 
heart defects (CHD) or 7-9% of all CHD diagnosed within the first year of life.  Before surgical 
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treatment became available, HLHS was universally fatal with 90% of deaths occurring in the 
first month of life [ Gutgesell H.P. et al, 1995]. 
HLHS is one of the many CHDs where cardiac malformations are characterized by poor 
growth of cardiac chambers and major blood vessels, subsequently impairing organ perfusion 
and oxygenation. In HLHS, the poor development of the left-sided structures is likely to be due 
to an underlying genetic defect [Seema Mittal et.al, 2013] . At present the etiology or the 
molecular abnormalities in HLHS remain unknown. Currently no studies have shown a clear 
association of genetic factors to HLHS, however, a high incidence of CHD in the first degree 
relatives, suggesting an autosomal recessive mode of inheritance, and familial clustering as well 
as association with chromosomal abnormalities like Turner’s syndrome, trisomies 13 and 18 ; 
and terminal deletion of 11q23-qter have been reported [Hinton RB et al, 2007;  Sedmera D. et 
al, 2005; Shokeir MH et al, 1971; Madhu Gupta et al ,2008]. These reports collectively suggest a 
possible role of genetic factors in the etiology of HLHS.  The aim of this study is to explore the 
genetics of HLHS through a novel mouse model and further perform functional studies to gain 
better understanding of the etiology of HLHS. 
 
 
1.3 HYPOPLASTIC LEFT HEART SYNDROME HUMAN STUDIES 
Some interesting insights have helped us in understanding the etiology of HLHS. Almost all of 
these studies are based on findings from HLHS patients, as there as has been no animal model 
for HHLS. In 2003, Teresa J Bohlmeyer et al studied the heart tissue from patients with HLHS 
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using routine histology, immunohistochemistry. The HLHS hearts in her study showed 
disorganized muscle fibres, myocytes were smallers with scanty cytoplasm, and abundant 
connective tissues.  [Teresa J Bohlmeyer et al, 2003] 
Hinton et al, 2007 conducted a study at Cincinnati Children’s Hospital, to determine the 
heritability in families identified by a HLHS proband. A total of 38 probands with HLHS, a 3-
generation family history was obtained and a total of 235 participants were recruited.  They 
found the heritability of HLHS alone and with associated CVM was 99% and 74% (p < 
0.00001), respectively. The sibling recurrence risk for HLHS was 8%, and for CVM was 22%. 
The high heritability of HLHS as obtained from this study suggests that it is determined largely 
by genetic factors. Since the left- and right-sided valve dysplasia often co occurred in HLHS 
probands and the increased prevalence of bicuspid aortic valve (BAV) in family members 
suggested that HLHS is a severe form of valve malformation. [Hinton et al, 2007] 
However, the genetic etiology or the molecular abnormalities in HLHS remain unknown. 
Madhu Gupta et al 2008 did a study to provide a comparative expression analysis of HLHS and 
non-HLHS hearts.  Their comprehensive gene expression analysis of the atrial septum of HLHS 
and non-HLHS patients by microarray and identified chromatin remodeling, transcriptional 
regulation and cell cycle regulation to be altered in HLHS. Although this analysis proved to be 
very important in provided biological components that may be involved in HLHS, its limitation 
was in the fact if the findings from the atrial septum could be applied to the global effects of the 
left ventricle in HLHS. [Madhu Gupta et al 2008] 
Ricci et al, 2012, studied the right ventricle (RV) of six neonates with HLHS and 
compared it to the RV and left ventricle (LV) from non-diseased control subjects using a 
genome-wide exon array analysis to determine differentially expressed genes and alternatively 
6 
spliced transcripts. In HLHS, over 180 genes were differentially expressed and 1800 were 
differentially spliced, resulting in changes in a variety of biological processes involving cell 
metabolism, cell adherence and cytoskeleton. (Fig 3) [Ricci et al, 2012] 
Figure 3. Pathway analysis of human studies. 
KEGG pathway analysis to show the relative significance of affected biological processes 
in HLHS-RV samples versus controls as a result of differential gene expression and alternative 
splicing events. Numbers indicate the number of differentially expressed or alternatively spliced 
transcripts that within each indicated KEGG category. [Ricci et al 2012] 
In 2013, Seema Mittal at el, for the first did a study on human fetuses at LV and right 
ventricle (RV) paired myocardial samples were obtained from 32 second-trimester fetuses with 
HLHS.  Their results suggest that the fetal LV in HLHS undergoes reprogramming with decrease 
in cardiac lineages and increase in fibroblast lineages. This process involves TGFB 1 up-
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regulation, DNA damage, premature cell senescence, and loss of DNA replication association 
with impaired cardiac differentiation and vasculogenesis. [Seema Mittal at el.2013] 
The results from these studies have been very exciting and important discoveries in the 
understanding the etiology of HLHS. However, to gain a detailed insight into its genetics and 
treatment options would only be possible in the presence of an animal model. 
1.4 GENETICS OF LEFT VENTRICULAR HYPOPLASIA 
In elucidating the genetics of HLHS, a question important to address is why HLHS is a LV 
specific phenotype. It is thus crucial to understand the genetics of LV development and 
hypoplasia. 
LV hypoplasia describes a lethal congenital heart abnormality that usually occurs in 
association with obstruction to LV outflow. [Edward.J.Hickey et al 2012].  The majority of cases 
of LV hypoplasia occur in association with downstream obstruction, which in most cases is 
aortic stenosis. Therefore, it has been suggested that LV hypoplasia is predominantly a disease of 
the aortic valve [Hinton et al 2007].  But the discoveries of 2 basic helix-loophelix transcription 
factors—HAND-1 and HAND-2, which appear central to early ventricular development, suggest 
that in some cases, the primary defect is in the ventricle itself. 
During initial development of the heart tube, HAND expression is almost uniform, in 
both the ventricles, but marked differences in expression are then seen in the craniocaudal axis in 
a ventricle-specific fashion [Srivastava et al.1999].  HAND-1 transcripts are expressed in the 
conus arteriosus, truncus arteriosus, primitive atrium, and primitive ventricle, but their 
expression is significantly deficient in the bulbus cordis, which is the future right ventricle. ON 
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the other hand, HAND-2 is predominantly expressed in the bulbus cordis. It can therefore be 
inferred that mutations in HAND-1 are associated with LV hypoplasia and abnormalities in 
LVOT development [Srivastava et al 1997].  
Experiments have suggested that loss-of-function mutations result in non-viable fetuses 
due to lack of development of the left and right ventricles. Some gene-sequencing studies of 
human hearts affected by LV hypoplasia have recently demonstrated loss-of-function mutations in 
HAND-1 in a large proportion [Edward.J.Hickey et al 2012]. 
Apart from the HAND genes, the T-box (Tbx) genes are also important in cardiovascular 
development. Persistent overexpression of Tbx5 results in heart looping defects, abnormalities of 
early chamber development and loss of ventricular-specific gene expression, indicating an 
essential role for Tbx5 in early heart development [Horb and Thomsen, 1999; Hatcher et al., 
2001; Liberatore et al., 2000]. Studies have shown that Tbx5 expression is restricted to the atria 
and the left ventricle. Hence, Tbx5 would provide a novel and valuable marker to explore the 
mechanism of LV hypoplasia [Bruneau et al., 1999; Yamada et al., 2000]. In the chick and 
mouse hearts Tbx5 is expressed ubiquitously, the ventricular walls are thinner than normal, and 
the trabecular formation is coarse and rough. These phenotypic changes indicate that Tbx5 
regulates cardiac muscle differentiation [J.K Takeuchi et al 2003]. 
Tbx5 protein associates and interacts physically with the cardiac homeoprotein Nkx2.5, 
which is important for cardiac muscle development (Bruneau et al., 2001; Hiroi et al., 2001). 
Interactions between Tbx5 and GATA4 activate the atrial natriuretic factor (ANF) promoter. 
These studies support that Tbx5 plays multiple roles and changes in its protein level in 
differentiating cardiomyocytes might affect the transcriptional control of cardiac genes by 
disturbing the balance of these multiple interactions. Both the loss and gain of Tbx5 function 
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disturb the transcriptional control of Tbx5 targets, probably through the abnormal balance 
between the Tbx5, Tbx20, GATA4 and Nkx2.5 proteins [Edward.J.Hickey et al 2012]. 
Although, the above mentioned findings have aided us in our understanding of the 
genetic basis of LV hypoplasia, the lack of an animal model, makes it difficult for us to analyze 
the changes in development of LV in HLHS hearts.      
1.5 INTRODUCTION TO ENU MUTAGENESIS 
Lack of an animal model for HLHS has been a limiting factor to further interrogate the genetic 
and molecular basis of its etiology.  The phenotype-based forward genetic approach that is 
carried out on the LoLab serves as an excellent avenue to identify important genes based on their 
mutant phenotype; hence all biases based on protein structures, gene expression patterns, or 
knowledge on their homologues in other species is excluded. 
N -Ethyl- N - Nitrosourea (ENU) is a powerful alkylating agent that generates single 
nucleotide substitutions (both transitions and transversions) in mouse spermatogonia at a 
frequency of one point mutation every 1 to 2 megabases throughout the genome [Kile 2005].  
The single nucleotide mutations thus induced may simulate many human genetic conditions and 
serves as better disease models than the deletions and transgene insertions as a result of reverse 
genetic manipulation [Anderson KV. 2000].  Typically, C57BL/6J mice (G0) are ENU 
mutagenized and the resulting G1 males and their G2 daughters are backcrossed to generate G3 
fetuses for ultrasound scanning to recover recessive mutations causing CHD.  (Fig 4) 
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Figure 4. ENU mouse recessive mutagenesis and breeding scheme. 
C57BL/6J mice (G0) are ENU mutagenized and the resulting G1 males and their G2 daughters 
are backcrossed to generate G3 fetuses for ultrasound scanning to recover recessive mutations 
causing congenital heart disease (CHD). 
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2.0  METHODS AND MATERIALS 
2.1 ULTRASOUND IMAGING AND DOPPLER ECHOCARDIOGRAPHY 
ENU mutagenized pregnant G2 females were sedated with isoflurane, and ultrasound scanned 
using the Acuson Sequoia C512 with a 15 MHz transducer. Litters with abnormal fetuses were 
then further scanned using the Vevo2100 UBM with 40MHz transducer for specific CHD 
diagnosis. (Fig 5) 
 
2.2 NECROPSY, MICRO CT IMAGING AND HISTOPATHOLOGY 
EXAMINATIONS 
Fetuses or neonates were collected and fixed in 10% formalin, then examined by necropsy, 
micro-computed tomography (micro-CT) or magnetic resonance imaging (micro-MRI) and 
episcopic fluorescence image capture (EFIC) [Rosenthal J, ET AL 2004], a histopathology 
examination. EFIC served as the gold standard for CHD diagnosis. (Fig 5) 
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Figure 5. Workflow of ENU screening in the Lo lab.
(Please note that this figure was adapted from a figure presented by Dr. Xiaoqin Liu in the Lo lab) 
2.3 DNA ISLOLATION 
Skin samples collected from fetuses or neonates were snap frozen in liquid nitrogen and DNA 
was extracted using Gentre Pure genelysis buffer (QIAGEN), followed by DNA purification 
(QIAGEN).  The DNA thus obtained was used for exome sequencing. 
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2.4 EXOME SEQUENCING 
Two mutant mice from Family 635 were sequence captured using Agilent SureSelect Mouse All 
Exon kit, and sequenced using SOLiD 4 sequencer.  Over 100x target coverage were achieved 
for each exome. Sequence reads were aligned to C57BL/6J mouse reference genome (mm9) and 
analyzed using LifeScope software (Life Technologies).  Sequence variants were annotated with 
annovar (http://www.openbioinformatics.org/annovar/) and filtered against dbSNP128 and our 
in-house database with custom scripts.   Novel homozygous coding variants present in both 
mouse exomes were identified as candidate disease causing mutations. (Fig 6) 
 
            
Figure 6. Whole Exome Sequencing Analysis Workflow. 
(Please note that this figure was adapted from a figure presented by Dr.You Li in the Lo lab) 
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2.5 GENOTYPING 
Tail snips from fetuses and neonates were lysed overnight using standard protocols. The DNA 
thus obtained was used for genotyping by PCR amplification using Roche PCR kit. Primers were 
designed using Primer3 (http://primer3.ut.ee/).  List of primers used are provided in Table 1. 
Table 1. List of primers used for genotyping of HLHS mouse line. 
Primer Name 
        Forward Primer          Reverse Primer 
  mG-Sap130 TTTTTACCCTCTTTTCAGGATCT AAGTCAAATTCAGAGTTGCTTTG 
mG-Pcdha9 ACCTGATCATTGCCATTTGC TCTGGGACACACATTTGTCAT 
mG-Pepd TAGCCCAGGCAGAGCTTA GCGGTGTCTGTCAGTCAA 
mG-NADsyn1 ATGGGTACCCTGAAGCTCCT TCTCTTCAGCGGCTATGGAT 
 mG-Esco1 AACAAGCCTGTTTCCCATGA TTGGGAAAAATTGAGGAAGAG 
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2.6 RNA EXTRACTIONS, REVERSE TRANSCRIPTION 
Total RNA from mouse embryos was isolated using RNeasy micro kit with on-column DNase I 
digestion method (QIAGEN). cDNA libraries were produced from RNA extracted by using High 
capacity RNA to cDNA kit (Applied Biosystems). 
2.7 BIOINFORMATICS ANALYSIS  
EdgeR analysis was used for identifying differentially expressed genes.  GO terms KEGG 
pathways were obtained using the DAVID (http://david.abcc.ncifcrf.gov/chartReport.jsp).  
2.8 PATHWAY ANALYSIS VALIDATION BY REAL TIME PCR 
Real-time PCR was done using Applied Biosystem HT7900 with Power SYBR Green PCR 
Master Mix (Applied Biosystem) following standard protocol. β-actin gene, which is 
ubiquitously expressed, was used as an internal control. Primers were designed Roche Universal 
Probe Library.  The Primer sequences are listed in Table 2. 
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Table 2. List of Real-Time primers used for validation of RNAseq transcriptome profiling.
2.9 IMMUNOSTAINING 
Embryos were fixed overnight in 4% Paraformaldehyde, dehydrated through graded ethanol, and 
paraffin embedded. Sections were cut at 8 μm and mounted on Poly-Prep slides (Poly-L-lysine 
coated by Sigma). The antigens were retrieved by incubating in the 20XBulls eye decloaker 
(Biocare medical) for 40 minutes at 100 C. The source and concentration of primary antibodies 
are: anti-Phospho-histone H3 (1:100 dilution) (Millipore,Ser10), anti-MF 20 (1:100 dilution) 
(Developmental Studies Hybridoma Bank), Further, sections were incubated with secondary 
antibody AF555-goatanti-rabbit IgG(1:000) and AF488 Goat anti-mouse IgG2b(1:1000), WGA 
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(1:200 dilution) (Developmental Studies Hybridoma Bank). AF-488 Donkey anti-goat 
IgG.Nuclei were stained with DAPI (1:5000). Coverslips were mounted using Vectashield 
(Vector laboratories,Inc).Terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end 
labeling (TUNEL) assays were performed using the Roche (Ref#12156792910) by following the 
manufacturer's recommendations. Sections were visualized under Olympus Confocal 
microscope. Quantitative analysis was performed on Nikon elements at Centre of biological 
imaging, University of Pittsburgh. 
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3.0  RESULTS 
3.1 RECOVERY AND ANALYSIS OF HLHS MOUSE MODEL 
From ultrasound scanning over 60,000 fetuses thus far, most of the CHD found in the clinical 
setting were detected in our screening, including ventricular septal defects (VSD), Double outlet 
right ventricle (DORV), Persistent Truncus Arteriosus (PTA), Atrioventricular Septal Defects 
(ASD) to name a few.  Detailed lists of CHDs recovered from our ENU screen is below. 
                       
Figure 7. List of CHD seen clinically that were observed in our screen. 
                 We recovered 7 HLHS mutants after screening a total of 60,000 fetuses.  
(Please note that this figure was adapted from a figure presented by Dr. Xiaoqin Liu in the Lo lab) 
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The most novel among these findings was the recovery of 7 HLHS mutants in six 
independent mouse lines.  This finding is indeed very exciting because prior to the recovery of 
our HLHS mouse model it was widely believed that HLHS could not be modeled in mice due to 
its short gestation period of only 20 days. Further analysis by necropsy followed by EFIC 
histology confirmed the diagnosis of HLHS. Which by definition includes the finding of LV 
hypoplasia, hypoplastic aorta, hypoplastic mitral valve, and absence of VSD.  (Figure 8) 
Figure 8. Six independent mouse lines with HLHS models that were recovered in our ENU screen. 
(Please note that this figure was adapted from a figure presented by Dr. Xiaoqin Liu in the Lo lab) 
Among these six lines we further bred line 635, where we had recovered two mutants 
from the original screen, named Ohia to recover more mutants to validate our HLHS model.  It is 
interesting to note that our Ohia mutants exhibit craniofacial defects such as microcephaly, low 
set ears, proboscis, recessed or absent lower jaw. Craniofacial defects have also been 
documented in several HLHS patients [Aparna VP et. al 2013, Licht DJ et al 2009, Tracy A. 
Glauser et al 1990], suggesting a neurodevelopmental involvement in the pathophysiology of 
HLHS.  (Fig 9) shows the classical phenotype of HLHS in Ohia mutants. 
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Figure 9. HLHS mutants in line Ohia. 
HLHS mutants in line Ohia shows craniofacial defects with microcephaly, proboscis, low 
set ears (A, E), Necropsy images of HLHS hearts showing classical HLHS phenotype (B,F), 
which are confirmed by histopathology showing hypoplastic left ventricle (LV) ,  hypoplastic 
aorta,  mitral valve atresia/stenosis (C,D,G,H). 
3.2 CARDIOMYOCYTE PROLIFERATION IS INCREASED IN HLHS 
In order to determine whether cardiomyocytes proliferation was altered in HLHS mutants, hearts 
harvested from E14.5-E16.5 and P0 (newborn) mutants and their littermate controls were 
immunostained for Cell proliferation marker and cardiomyocyte marker (MF20).   HLHS hearts 
demonstrated an increased cardiomyocyte proliferation on the left ventricle. Expression of 
phospho-histone H3 (pHH3), which relates to mitotic chromosomal condensation, was 
significantly higher in HLHS mutants compared to in littermate control. In separately analyzing 
21 
the LV vs the RV, it can be noticed that most of the difference between mutatns and controls is 
accounted for by the significant differences in the LV alone between the two groups. (P-values at 
E14.5=0.0398, E15.5=0.2508, E16.5=0.0043, P0=0.0225). 
Interestingly, increased cardiomyocyte proliferation was also observed on the right 
ventricle but it was not significantly different between controls and mutants. Taken together, this 
data demonstrates that left ventricle of HLHS mice in line Ohia have increased cardiomyocyte 
proliferation. 
Figure 10. Increased expression of Phospho-histone H3 (Ph3) in the left ventricles of HLHS mutant 
hearts in line Ohia. 
Control-LV HLHS-LV
Dapi 
MF20 
Ph3 
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Figure 11. Graphs representing increased cardiomyocyte proliferation in left ventricle of Ohia       
mutants at E14.5, E15.5, E16.5 and newborn (P0) developmental stages. 
3.3 INCREASED APOPTOSIS AND CARDIOMYOCYTE SIZE IN HLHS  
TUNEL staining of hearts harvested at E14.5-E16.5 and P0 from HLHS mutants and littermate 
controls demonstrated an increase in apoptosis in HLHS mutant left ventricles in comparison to 
littermate controls. HLHS mutants had significantly higher percentage of apoptosis compared to 
in littermate controls. (P-value at E14.5=0.0001, E15.5=0.0209, E16.5=0.3012)  
Cardiomyocyte size was measured to rule out hyperplasia versus hypertrophy of 
individual cardiomyocytes. Our data suggests that during later stages of development, there is an 
increase in the cardiomyocyte nuclear size in left ventricles of HLHS mutants in line Ohia. 
(Figure 14) 
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Figure 12. TUNEL staining of Ohia mutants shows increased apoptosis (arrows) in the left ventricle 
when compared to the control. 
Figure 13. Graphs representing increased apoptosis in Ohia mutants at developmental stages of 
E14.5, E15.5, E16.5 and newborn (P0).
HLHS-LV
Dapi 
TUNEL 
Control-LV
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Figure 14. Increase in cardiomyocyte nuclear size in HLHS left ventricle at E16.5 and newborn 
mutants. 
3.4 TRANCRIPTOME PROFILING OF HLHS MUTANTS SHOWS 
PERTURBATIONS IN MITOCHONDRIAL AND CELL SIGNALING PATHWAYS 
To obtain a global view of gene expression in HLHS mutant hearts, we measured gene 
expression in E13.5, E14.5 and E18.5 heart tissues by RNA-seq.  For the E13.5 samples we 
dissected the hearts into left and right ventricles separately. For E14.5 and E18.5 whole heart 
samples were used. A total of 4176 differentially expressed (DE) genes were obtained with a 
false discovery rate (FDR) of < 0.05.   These 4176 genes were further categorized as up and 
down regulated genes in the HLHS mutants in comparison to their littermate controls, followed 
by pathway analysis using DAVID.   The up regulated genes were enriched in pathways related 
to cancer, Focal adhesion, regulation of cytoskeleton, axon guidance, Wnt signaling, 
extracellular matrix and TGF-beta signaling (Figure 17).   Down regulated genes involved in 
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Parkinson’s, Alzheimer’s and Huntington’s diseases which are primarily genes related to 
mitochondrial function. Further, we performed Q-PCR experiments to validate some of the 
highly expressed genes (fold change >0.5) in enriched pathways. 
Figure 15. Multi-dimensional scaling (MDS) plot for HLHS samples.
Multi-dimensional scaling (MDS) plot for samples at E13.5, E14.5, and E18.5, 
segregated by developmental stages (A). (B) Shows a MDS plot for samples at E18.5 and E14.5 
segregating by phenotype; HLHS or littermate controls. 
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Figure 16. Heat map of top 100 differentially expressed (DE) genes, showing the segregation on 
HLHS samples separately from their littermate controls. 
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Figure 17. Pathway enrichments in up and down regulated genes in HLHS mutants. 
Among the genes enriched in the pathways of cancer (total 74), several genes were 
involved in apoptosis and cell proliferation. There were integrins, genes from the TGFB super 
family, Wnt signaling, growth factors and transcription related genes. (Figure 18) 
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Figure 18. Genes enriched in the pathways of cancer. 
 
Next we separately analyzed at the E13.5 samples, with RNA-seq results from left and 
right ventricle.  We wanted to look at the transcriptome profiling of genes that behave differently 
not only in HLHS mutants and their littermate but also in the left versus right ventricles.  This 
analysis yielded us 46 DE genes, showing perturbations in pathways related to cell adhesion, 
Extracellular matrix, collagen and cytoskeletal organization, dilated and hypertrophic 
cardiomyopathies. (Figure 19) 
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Figure 19. Trancriptome profiling and pathway analysis of HLHS LV and RV tissue. 
(A) MDS plot showing the segregation of HLHS mutants and littermate controls based on 
side as well as phenotype. (B) Heat map showing the 46 DE genes that behave differently on the 
LV in comparison RV in both mutants and controls.  (C) Pathway enrichments in up and down 
regulated DE genes in the left ventricle of HLHS mutants and their littermate controls.  
Q-PCR experiments were performed for some DE genes in major pathways to compare 
their relative expressions on the LV versus the RV at stages E14.5 and E17.5. (Figure 20,21, 22 
and 23). Some differences in expression could be accounted for by difference in developmental 
stages. 
Figure 20. Upregulation of BMP4, VEGFA and TGFB2 in the LV of HLHS mutants in line Ohia. 
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Figure 21. Up regulation of WNT9B, FGF11 and COL2A1 in the LV of HLHS mutants in line Ohia. 
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Figure 22. Up regulation of FN1, ITGAV and ITGB5 in the LV of HLHS mutants in line Ohia. 
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Figure 23. Down regulation of COX8A, COX5B and BRP44L in the LV of HLHS mutants in line 
Ohia. 
All in all, our transcriptome profiling analysis, yielded us results that were strikingly 
similar to those obtained in Ricci et al 2012 stud, comparing HLHS RV to Control RV and LV. 
(Figure 24) 
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Figure 24. Highlighted in red are KEGG pathways and biological processes which overlap between 
our analysis and Ricci et al 2012. 
3.5 RECOVERY OF MUTATIONS IN OHIA MUTANT LINE 
Although previous studies have concluded that HLHS is heritable [Hinton et al 2007] but no 
causative genes have been identified till date.  Our whole exome sequencing analysis aided us in 
identifying five candidate genes on chromosome 18 and 7. (Table 3).  We further validated the 
splicing mutation in Sap130, which is a transcriptional co repressor in Sin3A-HDAC complex 
and is possibly involved in chromatin remodeling. This validation demonstrated that our 
mutation in Sap130 has three spliceforms. (Figure 25). Two spliceforms result in a premature 
truncation of the protein. 
35 
Table 3.Whole exome sequencing of Ohia mutants revealed five mutations on chromosome 18 and 7. 
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Figure 25. Gel picture of Sap130 spliceforms in homozygous animals harvested at E12.5. 
Homozygous animals show missing wild type band. 
Figure 26. Spliceform 1 of Sap130 shows 76 bp insertion in intron 10. 
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Figure 27. Spliceform 2 in Sap130 shows in frame mutation with deletion of exon 10 (105bps). 
Figure 28. Spliceform 3 in Sap130 shows skipping on exon 9 and 10. 
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Figure 29. Summary of three spliceforms of Sap130 in line Ohia. Spliceform 1 and 3 result in 
premature truncated protein. 
 
These five candidate genes helped us in setting up our matings for Ohia, and we validated 
our model with 15 more HLHS mutants. Interestingly in line Ohia, some mutants were not 
classical HLHS and had only a hypoplastic left heart (HLH) and a normal aortic and mitral 
valve.  We further analyzed these 15 HLHS mutants and a total of 109 age matched littermate 
controls by using a decision tree analysis. (Figure 30).  
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Figure 30. Genotypes of 15 HLHS mutants and 8 HLH mutants. Decision tree analysis of HLHS 
mutants with ROC=0.085. 
Our decision tree analysis is indicates that Sap130 and Pcdha9 are the two of the five 
genes that are probably the most important candidate genes for HLHS in line Ohia. A Receiver 
operator curve (ROC) of more than 0.5 signifies that this prediction was not random.      
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4.0  DISCUSSION 
Hypoplastic left heart syndrome (HLHS), is a rare CHD. Very little is known about the genetic 
basis of its etiology.  Our study presents the successful recovery of the first HLHS murine model.  
Our HLHS model in line Ohia, exhibits the classical cardiovascular features of HLHS along with 
craniofacial defects such as proboscis, absent lower jaw, low set ears, which have been 
previously documented in HLHS patients.   
Ohia mutants show increased cardiomyocyte proliferation in the left ventricles at E14.5, 
E15.5, E16.5 and newborns. This increase in proliferation could be suggestive of defects in cell 
cycle regulation, which we would like to explore in our future studies. In addition, to 
proliferation, HLHS LV’s showed increased in apoptosis.  The increase in apoptosis on the left 
ventricle could possibly be responsible for the hypoplastic LV, but the exact mechanisms that 
triggers the apoptotic cascade is yet to be studied.  
Our transcriptome profiling analysis from E13.5, E14.5 and E18.5 Ohia hearts helped us 
to identify 4176 differentially expressed genes. The up-regulated genes were highly enriched in 
pathways on cancer, focal adhesion, regulation of cytoskeleton, axon guidance, Wnt and TGFβ 
signaling and ECM receptor interaction, Up regulation of Wnt, TGFβ signaling and ECM 
receptor interaction pathways is suggestive of their role-play in the valve development [Jan-
Hung Chen et al 2011] in our HLHS mutants.  The up-regulated pathways encompassed several 
genes that were pro-apoptotic and were involved in increased cell proliferation, which validates 
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our findings of increased proliferation and apoptosis.  Our analysis, showed the up-regulation of 
a number of integrins (ITGAV, ITGA3, ITGA6), which are involved in valve condensation and 
maturation [Borg and Terracio, 1990] 
Down-regulated pathways demonstrated a global effect of mitochondrial dysfunctions, by 
showing perturbation in oxidative phosphorylation, Parkinson’s, Huntington’s and Alzheimer’s 
disease pathways.  Mitochondrial dysfunction has been well documented to play a role in CHD 
by inducing in utero hypoxia, loss of redox control and eventually cell death [L.Hool 2010].  
Interestingly, our trascriptome analysis showed strikingly similar results as the study 
done by Ricc et al, 2012; using HLHS RV samples, indicating that our HLHS model indeed is a  
bonafide HLHS disease model.  
Our whole exome data sequencing analysis has helped us to identify five candidate genes 
as identified from four ENU recovered mice.  Further breeding has helped us to narrow our 
candidate genes to two genes that may be involved in the genetic etiology of HLHS in Ohia. 
Mutation in Sap130, a transcriptional co-repressor in Sin3A-HDAC complex, is suggestive of the 
involvement of chromatin remodeling in our model. Mutation in Pcdha9 is indicative cell-
adhesion and cell-migration dysfunction.  This is also reflected from our transcriptome profiling, 
which shows enrichment of pathways of cancer, ECM-related genes, Integrins and Laminins. 
Based on the findings from our study, we would hypothesize that HLHS phenotype is 
brought together in a piecemeal pattern.  There are perturbations in genes/pathways that are 
responsible for the valve phenotype (eg. Integrins, TGFB and Wnt pathway, ECM 
maladaptation); and other pathways/genes which account for the hypoplastic LV phenotype, such 
as mitochondrial dysfunction, increased apoptosis in LV and increased proliferation.  Chromatin 
remodeling probably has a more global role in the etiology of our HLHS mouse model.  
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5.0  CONCLUSION 
In conclusion, we generated the first mouse model of HLHS and showed it closely models the 
structural heart defect and gene expression changes seen in HLHS patients. Interestingly, Ohia 
mutants also exhibited craniofacial anomalies similar to HLHS patients.  Our findings suggest 
HLHS is accompanied by disruption of mitochondrial respiration and energy metabolism. We 
also see up regulation of genes involved in extracellular matrix interaction, TGFB and Wnt 
signaling, cell proliferation, and cell death.  Genes altered in our transcriptome profile represent 
suggests perturbation in valve development, suggesting that the HLHS phenotype may involve 
valve disease. Further studies are needed to determine if the LV hypoplasia my arise downstream 
of improper valve development of whether it is due to cell intrinsic defects that may affect cell 
proliferation and cell survival. Using this mouse HLHS model, we will be able to interrogate the 
developmental pathways and molecular mechanism that cause HLHS. 
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